Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience

Yi Li,1,* Yizhao Xie,1,* Chengcheng Gong,1 Yannan Zhao,1 Jian Zhang,1 Sheng Zhang,1 Leiping Wang,1 She Chen,2 Xichun Hu,1 Biyun Wang1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Y, Xie Y, Gong C, Zhao Y, Zhang J, Zhang S, Wang L, Chen S, Hu X, Wang B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	fulvestrant everolimus exemestane metastatic breast cancer endocrine therapy. Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e1b4f99a21dc4a6780fe74ce220f0b01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1b4f99a21dc4a6780fe74ce220f0b01
record_format	dspace
spelling	oai:doaj.org-article:e1b4f99a21dc4a6780fe74ce220f0b012021-12-02T11:57:42ZComparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience1178-203Xhttps://doaj.org/article/e1b4f99a21dc4a6780fe74ce220f0b012020-06-01T00:00:00Zhttps://www.dovepress.com/comparative-treatment-patterns-and-outcomes-of-fulvestrant-versus-ever-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XYi Li,1,* Yizhao Xie,1,* Chengcheng Gong,1 Yannan Zhao,1 Jian Zhang,1 Sheng Zhang,1 Leiping Wang,1 She Chen,2 Xichun Hu,1 Biyun Wang1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People’s Republic of China; 2Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, People’s Republic of China*These authors contributed equally to this workCorrespondence: Biyun Wang; Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, #270 Dongan Road, Xuhui District, Shanghai 200032, People’s Republic of ChinaEmail wangbiyun0107@hotmail.com; huxichun2017@163.comBackground: Fulvestrant (FUL) and the combination of everolimus and exemestane (EVE-EXE) were the options to treat hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) patients who were refractory to aromatase inhibitors (AIs). The practical knowledge of treatment patterns and outcomes between the two regimens is essential for improving treatment decisions.Methods: HR+/HER2− MBC patients, who were refractory to AI, were treated with FUL or EVE-EXE from June 2013 to June 2016 were included. Treatment patterns, progression-free survival (PFS), overall survival (OS), and toxicity were reported. Propensity score matching (PSM) was used to minimize potential confounders.Results: A total of 168 patients were enrolled. Of 168 patients, 124 patients were treated with FUL and 44 patients received EVE-EXE. Patients who were treated with EVE-EXE were younger, more likely to have visceral, liver, multiple sites of metastases, and had received more prior chemotherapy. After adjusting for propensity score matching (PSM), no significant difference in PFS was found between two groups (P=0.419). However, in the subgroup of multiple metastatic sites, the median PFS was significantly improved in the EVE-EXE arm compared with FUL arm (6.1 vs 3.2 months, respectively, P=0.012). More patients in EVE-EXE arm discontinued treatment due to adverse events than in the FUL arm.Conclusion: A substantial difference in treatment patterns was observed between the two arms. Clinical outcomes were comparable after PSM.Clinicaltrials.gov Identifier: NCT03695341 (May 14, 2018).Keywords: fulvestrant, everolimus, exemestane, metastatic breast cancer, endocrine therapyLi YXie YGong CZhao YZhang JZhang SWang LChen SHu XWang BDove Medical Pressarticlefulvestranteverolimusexemestanemetastatic breast cancerendocrine therapy.Therapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 607-615 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	fulvestrant everolimus exemestane metastatic breast cancer endocrine therapy. Therapeutics. Pharmacology RM1-950
spellingShingle	fulvestrant everolimus exemestane metastatic breast cancer endocrine therapy. Therapeutics. Pharmacology RM1-950 Li Y Xie Y Gong C Zhao Y Zhang J Zhang S Wang L Chen S Hu X Wang B Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
description	Yi Li,1,* Yizhao Xie,1,* Chengcheng Gong,1 Yannan Zhao,1 Jian Zhang,1 Sheng Zhang,1 Leiping Wang,1 She Chen,2 Xichun Hu,1 Biyun Wang1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People’s Republic of China; 2Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, People’s Republic of China*These authors contributed equally to this workCorrespondence: Biyun Wang; Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, #270 Dongan Road, Xuhui District, Shanghai 200032, People’s Republic of ChinaEmail wangbiyun0107@hotmail.com; huxichun2017@163.comBackground: Fulvestrant (FUL) and the combination of everolimus and exemestane (EVE-EXE) were the options to treat hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) patients who were refractory to aromatase inhibitors (AIs). The practical knowledge of treatment patterns and outcomes between the two regimens is essential for improving treatment decisions.Methods: HR+/HER2− MBC patients, who were refractory to AI, were treated with FUL or EVE-EXE from June 2013 to June 2016 were included. Treatment patterns, progression-free survival (PFS), overall survival (OS), and toxicity were reported. Propensity score matching (PSM) was used to minimize potential confounders.Results: A total of 168 patients were enrolled. Of 168 patients, 124 patients were treated with FUL and 44 patients received EVE-EXE. Patients who were treated with EVE-EXE were younger, more likely to have visceral, liver, multiple sites of metastases, and had received more prior chemotherapy. After adjusting for propensity score matching (PSM), no significant difference in PFS was found between two groups (P=0.419). However, in the subgroup of multiple metastatic sites, the median PFS was significantly improved in the EVE-EXE arm compared with FUL arm (6.1 vs 3.2 months, respectively, P=0.012). More patients in EVE-EXE arm discontinued treatment due to adverse events than in the FUL arm.Conclusion: A substantial difference in treatment patterns was observed between the two arms. Clinical outcomes were comparable after PSM.Clinicaltrials.gov Identifier: NCT03695341 (May 14, 2018).Keywords: fulvestrant, everolimus, exemestane, metastatic breast cancer, endocrine therapy
format	article
author	Li Y Xie Y Gong C Zhao Y Zhang J Zhang S Wang L Chen S Hu X Wang B
author_facet	Li Y Xie Y Gong C Zhao Y Zhang J Zhang S Wang L Chen S Hu X Wang B
author_sort	Li Y
title	Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
title_short	Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
title_full	Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
title_fullStr	Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
title_full_unstemmed	Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
title_sort	comparative treatment patterns and outcomes of fulvestrant versus everolimus plus exemestane for postmenopausal metastatic breast cancer resistant to aromatase inhibitors in real-world experience
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/e1b4f99a21dc4a6780fe74ce220f0b01
work_keys_str_mv	AT liy comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT xiey comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT gongc comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT zhaoy comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT zhangj comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT zhangs comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT wangl comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT chens comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT hux comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience AT wangb comparativetreatmentpatternsandoutcomesoffulvestrantversuseverolimusplusexemestaneforpostmenopausalmetastaticbreastcancerresistanttoaromataseinhibitorsinrealworldexperience
_version_	1718394840750751744

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience

Ejemplares similares